Halloween is a special and spooky time of the year filled with costumes, candy and trick-or-treating. As families prepare to celebrate, Johns Hopkins Children’s Center experts are available for interviews on a variety of topics and tips to help ensure a safe and fun Halloween season.
BALTIMORE — More than 880 people attended the 13th Henrietta Lacks Memorial Lecture on Saturday, Oct. 7, virtually and in person at The Johns Hopkins Hospital’s Turner Auditorium.
A Johns Hopkins Children’s Center study of medical records concludes that delaying surgical treatment of the anterior cruciate ligament, or ACL, in some children is associated with a higher risk of new tears in the meniscus and cartilage after the initial injury to the ligament, which helps join the thigh bone to the shin bone.
Johns Hopkins Medicine experts lead the longest-running clinic for people with dwarfism and other skeletal conditions. Started in the late 1950s, the clinic, now called the Kathryn and Alan C.
Liquid biopsies are blood tests that can serially measure circulating tumor DNA (cell-free DNA that is shed into the bloodstream by dying cancer cells). When used in patients with advanced non-small cell lung cancer undergoing immunotherapy, they may identify patients who could benefit from treatment with additional drugs, according to a phase 2 clinical trial in the U.S. and Canada. The trial is led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, BC Cancer and the Canadian Cancer trials Group (CCTG).
Using laboratory-grown cells from humans and genetically engineered mice, scientists at Johns Hopkins Medicine say they have evidence that modifying a specific protein in immune white blood cells known as CD8+ T cells can make the cells more robust, potentially opening the door for better use of people’s own immune system T cells to fight cancer.
Treating cancer with immunotherapies known as an immune checkpoint blockade (ICB) prior to surgery (so-called neoadjuvant immunotherapy) has been a rapidly growing area of research, but the scientific community is just scratching the surface of what is possible, according to a review article co-authored by several current and former investigators from the Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins Kimmel Cancer Center.
Scientists have long understood that parts of cells, called organelles, evolved to have certain shapes and sizes because their forms are closely related to how they function.
Donlin M. Long, founding chair of the Johns Hopkins University School of Medicine’s Department of Neurosurgery and a pioneer in the treatment of chronic pain, died Sept. 19. He was 89.
For the past three years, nurse Lauren Chelenza has cared for hundreds of children with cancer while working on the pediatric oncology inpatient unit at Johns Hopkins Children’s Center in Baltimore. It’s a place she never imagined she’d be working 15 years ago, while going through her own cancer treatment.
Findings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19 have less chance of developing post-COVID conditions — commonly known as long COVID — if they receive early treatment with plasma from convalescent (recovered) COVID patients that contain antibodies against SARS-CoV-2, the virus that causes COVID-19.
How microbiota — microbes that live on human surfaces — impact cancer development and therapy has become an expansive area of research.
Patients with stage 1–3 non-small cell lung cancer (NSCLC) given a combination immunotherapy prior to surgery (neoadjuvant) had a better major pathological response (10% or less residual cancer) when the cancer was removed than those who took a single immunotherapy agent alone, according to results of a novel multicenter phase 2 NeoCOAST platform trial that included two investigators from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy. The results were published online Sept. 14 in Cancer Discovery, a journal of the American Association for Cancer Research.
September is National Sickle Cell Awareness Month. Johns Hopkins Medicine experts who specialize in sickle cell disease are available to speak with reporters about health equity issues related to sickle cell disease.
Researchers with the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine and four other institutions have developed a molecular test to identify the presence of brain tumors by measuring abnormal genetic material shed by tumors and circulating in cerebrospinal fluid (CSF). A description of the work was published Aug. 15 in the journal Cell Reports Medicine.
Thanks to a $24.5 million grant from the National Institutes of Health National Center for Advancing Translational Sciences (NCATS), Johns Hopkins Medicine today announced plans to continue with a trial innovation center (TIC) that will promote improvements in the efficiency and quality of National Institutes of Health-funded clinical trials across multiple disease areas.
A two-year study found that spikes of post-vaccination SARS-CoV-2 viral infections (commonly known as COVID-19 breakthrough cases) remain common, yet hospitalization rates have dramatically dropped following the first wave of the virus’ omicron subvariant.
A new study of mice and lab-grown human colon “organoids” indicates that an experimental drug developed by Johns Hopkins Medicine researchers can substantially reduce symptoms of inflammatory bowel disease (IBD) in pre-clinical models.
Deep-learning technology developed by a team of Johns Hopkins engineers and cancer researchers can accurately predict cancer-related protein fragments that may trigger an immune system response. If validated in clinical trials, the technology could help scientists overcome a major hurdle to developing personalized immunotherapies and vaccines.
The T. Boone Pickens Foundation, established by the late, Texan innovative energy leader and philanthropist, is donating $20 million to the Wilmer Eye Institute, Johns Hopkins Medicine.
Results of a long-term, federally funded study of cognitively healthy adults — most with a family history of Alzheimer’s disease — have added to evidence that low spinal fluid levels of a protein linked to learning and memory in mice may serve as an early predictor of mild cognitive impairment (MCI) years before symptoms appear.
A new review paper co-authored by two Johns Hopkins pain experts suggests that scrambler therapy, a noninvasive pain treatment, can yield significant relief for approximately 80%–90% of patients with chronic pain, and it may be more effective than another noninvasive therapy: transcutaneous electrical nerve stimulation (TENS). The write-up was published online July 13 in The New England Journal of Medicine.
New research in colorectal cancers directed by investigators at the Johns Hopkins Kimmel Cancer Center suggests that expression of transcription factors — proteins that help turn specific genes on or off by binding to nearby DNA — may play a central role in the degree of DNA methylation across the genome, contributing to the development of different subtypes of these cancers. Methylation is a process in which certain chemical groups attach to areas of DNA that guide genes’ on/off switches.
Based on findings from a study published today in the journal, The Lancet Regional Health – Americas, researchers at Johns Hopkins Medicine and three collaborating medical institutions suggest that people living with the human immunodeficiency virus (HIV) who donate a kidney to other people living with HIV (PLWH) have a low risk of developing end-stage kidney disease (ESKD) or other kidney problems in the years following the donation.
Giving patients with operable pancreatic cancers a three-pronged combination immunotherapy treatment consisting of the pancreatic cancer vaccine GVAX, the immune checkpoint therapy nivolumab and urelemab, an anti-CD137 agonist antibody treatment, is safe, it increases the amount of cancer-killing immune system T cells in the tumors and it appears effective when given two weeks prior to cancer-removal surgery, according to new research directed by Johns Hopkins investigators.
Improving diagnosis in health care is a moral, professional and public health imperative, according to the U.S. National Academy of Medicine.
In December 2021, 9-year-old Bryce Lampe of Edgewater, Maryland, began experiencing serious symptoms — a fever, vomiting, diarrhea, and body aches so intense he could barely move, causing him to sleep like a corpse, recalls his mother, Alexandra.
In a pre-clinical, proof-of-concept study from Johns Hopkins Medicine, researchers found that epigallocatechin gallate (EGCG), a green tea compound with powerful antioxidant properties, could be promising for both treating and preventing uterine fibroids. Results of the study, first posted online May 25 in Scientific Reports, add to growing evidence that EGCG may reduce fibroid cell growth.
Researchers at Johns Hopkins Medicine, in collaboration with researchers at the National Institutes of Health, report that two new studies in mice with a humanized immune system and human cell lines have identified an enzyme that plays a critical role in the late stages of HIV replication.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right